Author

Kenneth Kwok

UPDATE ON LABORATORY PARAMETERS RELATED TO MONITORING IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY
UPDATE ON LABORATORY PARAMETERS RELATED TO MONITORING IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY

Kenneth Kwok  et al.

MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME
MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

Kenneth Kwok  et al.

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME
CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Kenneth Kwok  et al.

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019
CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019

Kenneth Kwok  et al.

PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES: AN UPDATE AS OF FEBRUARY 2020
PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES: AN UPDATE AS OF FEBRUARY 2020

Kenneth Kwok  et al.

WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS
WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS

Kenneth Kwok  et al.

Item 1 - 6 / 6
1